BCR and autoimmune disease: Recently, we identified trogocytosis, whereby multiple key proteins, including BCR modulators and adhesion molecules, are stripped from the surface of B cells, as a potentially important MOA of epratuzumab in B-cell regulated autoimmune diseases [32].